MitraClip Therapy for Mitral Regurgitation: Secondary Mitral Regurgitation

Ted Feldman; Arjun Mehta; Mayra Guerrero; Justin P. Levisay; Michael H. Salinger

doi:10.1016/j.iccl.2015.08.007

MitraClip Therapy for Mitral Regurgitation: Secondary Mitral Regurgitation

Ted Feldman, Arjun Mehta, Mayra Guerrero, Justin P. Levisay, Michael H. Salinger

Cardiovascular Medicine

Research output: Contribution to journal › Review article › peer-review

10 Scopus citations

Abstract

Therapy for mitral regurgitation (MR) has been synonymous with mitral valve surgery. Operative approaches for degenerative MR repair have been associated with excellent results, with durable long term outcomes. Surgery for functional MR has been less successful. MitraClip has shown promise for functional MR, especiall in patinets who are high risk for surgery. The aggregate of nonrandomized global experience with MitraClip in functional MR has been consistent in showing improvements in symptoms and left ventricular remodeling. It remains to be seen how MitraClip therapy will compare with best medical therapy. The COAPT trial will clarify this question.

Original language	English (US)
Pages (from-to)	83-91
Number of pages	9
Journal	Interventional Cardiology Clinics
Volume	5
Issue number	1
DOIs	https://doi.org/10.1016/j.iccl.2015.08.007
State	Published - Jan 2016

Keywords

COAPT
Functional mitral regurgitation
MitraClip
Mitral regurgitation

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine

Access to Document

10.1016/j.iccl.2015.08.007

Cite this

@article{640404ecc7a54602a6a909f151cb7cbf,

title = "MitraClip Therapy for Mitral Regurgitation: Secondary Mitral Regurgitation",

abstract = "Therapy for mitral regurgitation (MR) has been synonymous with mitral valve surgery. Operative approaches for degenerative MR repair have been associated with excellent results, with durable long term outcomes. Surgery for functional MR has been less successful. MitraClip has shown promise for functional MR, especiall in patinets who are high risk for surgery. The aggregate of nonrandomized global experience with MitraClip in functional MR has been consistent in showing improvements in symptoms and left ventricular remodeling. It remains to be seen how MitraClip therapy will compare with best medical therapy. The COAPT trial will clarify this question.",

keywords = "COAPT, Functional mitral regurgitation, MitraClip, Mitral regurgitation",

author = "Ted Feldman and Arjun Mehta and Mayra Guerrero and Levisay, {Justin P.} and Salinger, {Michael H.}",

note = "Publisher Copyright: {\textcopyright} 2016 Elsevier Inc..",

year = "2016",

month = jan,

doi = "10.1016/j.iccl.2015.08.007",

language = "English (US)",

volume = "5",

pages = "83--91",

journal = "Interventional Cardiology Clinics",

issn = "2211-7458",

publisher = "Elsevier BV",

number = "1",

}

TY - JOUR

T1 - MitraClip Therapy for Mitral Regurgitation

T2 - Secondary Mitral Regurgitation

AU - Feldman, Ted

AU - Mehta, Arjun

AU - Guerrero, Mayra

AU - Levisay, Justin P.

AU - Salinger, Michael H.

PY - 2016/1

Y1 - 2016/1

N2 - Therapy for mitral regurgitation (MR) has been synonymous with mitral valve surgery. Operative approaches for degenerative MR repair have been associated with excellent results, with durable long term outcomes. Surgery for functional MR has been less successful. MitraClip has shown promise for functional MR, especiall in patinets who are high risk for surgery. The aggregate of nonrandomized global experience with MitraClip in functional MR has been consistent in showing improvements in symptoms and left ventricular remodeling. It remains to be seen how MitraClip therapy will compare with best medical therapy. The COAPT trial will clarify this question.

AB - Therapy for mitral regurgitation (MR) has been synonymous with mitral valve surgery. Operative approaches for degenerative MR repair have been associated with excellent results, with durable long term outcomes. Surgery for functional MR has been less successful. MitraClip has shown promise for functional MR, especiall in patinets who are high risk for surgery. The aggregate of nonrandomized global experience with MitraClip in functional MR has been consistent in showing improvements in symptoms and left ventricular remodeling. It remains to be seen how MitraClip therapy will compare with best medical therapy. The COAPT trial will clarify this question.

KW - COAPT

KW - Functional mitral regurgitation

KW - MitraClip

KW - Mitral regurgitation

UR - http://www.scopus.com/inward/record.url?scp=84947585249&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84947585249&partnerID=8YFLogxK

U2 - 10.1016/j.iccl.2015.08.007

DO - 10.1016/j.iccl.2015.08.007

M3 - Review article

C2 - 27852484

AN - SCOPUS:84947585249

VL - 5

SP - 83

EP - 91

JO - Interventional Cardiology Clinics

JF - Interventional Cardiology Clinics

SN - 2211-7458

IS - 1

ER -

MitraClip Therapy for Mitral Regurgitation: Secondary Mitral Regurgitation

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this